Sign in
CompletedPhase 4

S-Asenosyl-L-Methionine vs Placebo for Osteoarthritis of the Hands

Key facts

Who runs it
Dartmouth-Hitchcock Medical Center
Where
Lebanon, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 4
People taking part
40 people enrolled
Started
17 Aug 2022
Ended
11 Apr 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • S-Adenosyl-L-Methionine (Sam-E)
  • Placebo
Record updated
16 July 2025

Who can take part

Age
40 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Current primary care provider within the Dartmouth Health system
  • Office visit at Dartmouth Health in the past 3 years
  • Participants must be 40 or older at the time of signing the informed consent
  • Participants have discomfort or functional limitations of one or both hands AND either:; Objective findings of at least one hand meeting diagnostic criteria based on the American College of Rheumatology (ACR)* or; Existing radiographic evidence of osteoarthritis as judged by a radiologist
  • Patients taking OTC or prescription analgesics who are willing to stop their current analgesics for two weeks prior to study entry and remain off those medications over the course of the study
  • *Objective inclusion criteria (see poster schematic); Swelling or deformity of 2 of the following ten joints: the 2nd and 3rd distal interphalangeal (DIP) of each hand, the 2nd and 3rd proximal interphalangeal (PIP) of each hand, and the 1st carpometacarpal joints of both hands

Who cannot take part

  • Patients taking prescription medications other than NSAIDs for their OA who are unable to stop their medication
  • Patients taking any of the following medications at study entry OR starting any of these medications during the study period:; daily opioids (including tramadol or buprenorphine); gabapentin or pregabalin; prednisone; Prescription NSAIDs that they are unable to stop or topical diclofenac; SNRI drugs (Effexor, Cymbalta, Fetzima, Pristiq)
  • Patients with diagnoses of arthritis from conditions other than OA
  • Patients with Bipolar Disorder
  • The participant has a condition or is in a situation which, in the investigator's opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
  • Patients whose symptomatic joint is an artificial joint

Where in United States

  • Dartmouth Hitchcock Medical CenterLebanon, United States

About the trial

What the trial wants to find out

The primary objective of this study is to demonstrate the feasibility of evaluating SAMe tolerability, analgesic benefits, and daily functional improvement in patients with osteoarthritis of the hands compared to placebo. The secondary objective of this study is to generate preliminary data on discomfort, function, quality of life in patients with osteoarthritis of the hands when taking SAMe compared to placebo.

The 2 groups in the trial

  • S-Adenosyl-L-Methionine (SAMe)Treatment being tested

    Participants receive S-Adenosyl-L-Methionine (SAMe) 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period.

    Treatment: S-Adenosyl-L-Methionine (Sam-E) and Placebo

  • PlaceboPlacebo, for comparison

    Participants receive identically appearing 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period.

    Treatment: S-Adenosyl-L-Methionine (Sam-E) and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
S-Adenosyl-L-Methionine (SAMe) vs Placebo for Discomfort and Functional Limitations Associated With Osteoarthritis of the Hands: a Pilot Study
Record updated
16 July 2025